Avila pockets payment in $209M lung cancer drug deal

Avila Therapeutics (a 2010 Fierce 15 company) has banked $4 million from partner Clovis Oncology ($CLVS). The payment was made as part of Avila's $209 million alliance with Clovis (a 2009 Fierce 15 company) struck in 2010 to develop Avila's covalent inhibitor of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Avila said the payment was triggered after the FDA allowed Clovis' investigational new drug (IND) application for early trials of the compound, dubbed CO-1686, expected to kick off in the second quarter. Release

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.